Risk factors

NextCure is a clinical-stage biopharmaceutical company with an accumulated deficit of $380.1 million as of December 31, 2024. The company has prioritized the development of LNCB74, initiating its first clinical trial in January 2025. Manufacturing operations were paused in March 2024 following a restructuring, relying on third-party partners.

Concentrated exposure to industrial and retail real estate sectors drives revenue risks and property valuations. Major tenant concentrations, lease expirations, and debt maturities threaten cash flows and credit facility covenants. Geographic concentration in six states increases vulnerability to local economic downturns.

Oruka Therapeutics faces high clinical development risk, relying heavily on its two most advanced programs, ORKA-001 and ORKA-002, targeting PsO. The company depends heavily on external licensing partnerships like Paragon and must protect its intellectual property across a competitive biopharmaceutical landscape. Financial dilution, capital requirements, and strict regulatory and pricing hurdles also dominate its risk profile.

The company faces high concentration risks in its concrete segment centered in Texas and marine segment operating internationally.

Old Second Bancorp faces heavy exposure to commercial and residential real estate lending concentrations and market volatility. Growth strategies rely significantly on acquisitions and pending mergers, bringing integration and regulatory risks. Interest rate fluctuations and rising funding costs heavily impact net interest margin and profitability.

Specialty property, casualty, and insurance distribution risks dominate the business operations and growth strategy. Reliance on MGA partnerships, reinsurance capacity, and regulatory approvals creates significant exposure. Execution and integration risks from acquisitions and organizational restructuring could impact financial results.

Technology-focused BDC facing portfolio valuation risks, leverage and debt covenant limits, and merger integration challenges with OTF II.

Phathom Pharmaceuticals faces significant financial risks driven by heavy reliance on vonoprazan products like VOQUEZNA, substantial operating losses, and a reliance on third-party manufacturers.

Park-Ohio’s risk profile is dominated by cyclical automotive and heavy-duty truck market exposure, customer concentration, and raw material cost inflation driven by tariffs.

Prairie Operating Co. faces intense concentration risks in the DJ Basin, heavy reliance on the Bayswater Acquisition, and capital scarcity for its undeveloped reserves.

Priority Technology Holdings faces key risks related to payment processing competition, system outages, data security breaches, and heavy indebtedness.

Funding and liquidity pressure is prominent: 37% of deposits were uninsured, while large depositors, brokered deposits, and FHLB advances support funding.